Table 1 Cytotoxicity of tested compounds and doxorubicin towards cancer cell lines and normal cells as determined by the neutral red assay

1

52.24 ± 5.51 (>3.01)

145.63 ± 10.63 (>1.08)

>157.48

>157.48

>157.48

>157.48

>157.48

2

66.30 ± 6.19 (>2.23)

99.31 ± 8.46 (>1.49)

77.28 ± 8.77 (>1.92)

73.63 ± 3.52 (>2.01)

37.57 ± 2.59 (>3.94)

71.7 ± 4.52 (>2.07)

>148.15

3

>121.95

>121.95

>121.95

>121.95

>121.95

>121.95

>121.95

4

1.14 ± 0.02 (59.35)

0.27 ± 0.01 (250.59)

0.98 ± 0.11 (70.47)

0.07 ± 0.01 (966.57)

0.06 ± 0.01 (1127.67)

1.01 ± 0.08 (66.99)

67.66 ± 6.49

5

>238.10

>238.10

>238.10

>238.10

>238.10

>238.10

95.51 ± 5.64

6

>222.22

>222.22

>222.22

>222.22

161.92 ± 11.37

>222.22

>222.22

7

68.62 ± 7.55 ((>2.97)

87.91 ± 5.66 (2.32)

>204.08

89.72 ± 8.80 (>2.27)

64.59 ± 13.42 (>3.16)

176.17 ± 28.5 (>1.16)

>204.08

8

107.52 ± 17.95 (1.09)

8.05 ± 1.46 (1.09)

>168.07

63.93 ± 5.97 (2.27)

38.8 ± 3.33 (3.16)

94.22 ± 2.7 (1.16)

117.27 ± 1.22

9

27.35 ± 1.46 (3.48)

2.27 ± 1.52 (41.96)

46.62 ± 5.38 (2.04)

22.95 ± 0.13 (4.15)

16.94 ± 4.65 (5.62)

32.69 ± 0.61 (2.91)

95.24 ± 6.65

10

43.32 ± 2.72 (>2.87)

8.39 ± 0.48 (>14.81)

51.21 ± 5.54 (>2.43)

27.81 ± 2.03 (>4.47)

30.37 ± 8.64 (>4.09)

48.35 ± 3.73 (>2.57)

>124.24

11

50.26 ± 2.60 (0.88)

38.28 ± 3.23 (1.15)

45.37 ± 4.89 (0.97)

38.89 ± 2.35 (1.14)

22.56 ± 1.57 (1.96)

61.28 ± 5.53 (0.72)

44.20 ± 0.2

12

>129.45

>129.45

>129.45

>129.45

>129.45

>129.45

>129.45

13

47.53 ± 3.56 (1.96)

36.21 ± 3.08 (2.57)

25.09 ± 1.50 (3.72)

24.63 ± 2.71 (3.78)

9.25 ± 0.16 (10.08)

18.17 ± 1.46 (5.13)

93.21 ± 1.17

14

21.68 ± 1.50 (3.29)

3.14 ± 0.78 (22.72)

114.17 ± 3.68 (0.62)

>123.08

>123.08

114.60 ± 4.29 (0.62)

71.34 ± 5.23

Doxorubicin

1.01 ± 0.19 (0.58)

0.07 ± 0.01 (8.43)

0.37 ± 0.05 (1.59)

0.72 ± 0.13 (0.82)

0.35 ± 0.05 (1.69)

0.18 ± 0.03 (3.28)

0.59 ± 0.01